Executive Director, Global Projects Leader - Strategic Regimens

The Executive Director, Global Projects Leader (GPL) - Strategic Regimens will have overall leadership and accountability of multiple, global cross-functional early project teams delivering platform studies with embedded translational medicine research to establish proof-of-concept data enabling Phase III investment strategies. Each team will aim to prioritize and evaluate rational combination regimens across major AZ research platforms and treatment modalities and with the potential for external partnering. This individual will be accountable for the strategic leadership and execution for candidate combination regimens, aligning prioritization across early- and late-stage research units to advance the solid tumour pipeline. You will have oncology clinical drug development experience, demonstrated leadership, and be able to critically evaluate the science, clinical data and competitive landscape that underlies each program. You will be able to effectively communicate across a broad range of audiences and have an ability to clearly articulate project-specific strategies and deliverables as it relates to the overall AZ and Early Oncology vision.

• Leads global matrix teams that develop and execute Ph2 platform studies evaluating combination regimens through proof of concept leading to Phase III investment
• Responsible for ongoing linkage between early- and late-stage Oncology R&D teams to develop novel regimens with transformational potential and to maximize value of each asset
• Holds accountability for the strategy, budget, timeline and execution of platform studies and Ph3 supporting data generation  
• Ensures platform studies support life cycle management strategies and integrated product development plans of AZ’s emerging portfolio
• Leads and communicates the project development strategy at governance meetings to gain endorsement and to secure funding
• Leads the global project team to effectively communicate and manage risk; responsible for monitoring emerging data and for adjusting strategy when necessary
• Responsible for maintaining a high degree of team effectiveness through collaboration, influence, and, as necessary, coaching and mentoring of cross-functional team members
• Maintains relationships with external investigators to ensure projects are consistent with evolving clinical care and experimental approaches

Essential

• Graduate degree such as a PharmD, PhD, or an MD/PhD 10
• Industry experience in drug development including experience in early phase clinical drug development and regulatory knowledge
• Strong knowledge and understanding of the Oncology therapeutic area with experience in diverse biological modalities
• Understanding of the evolving clinical landscape in oncology
• Demonstrated experience leading and motivating teams in a highly matrixed environment
• Proven record of cultivating and managing internal and external cross-functional collaborations
• Demonstrated success in influencing colleagues and senior leaders in various departments
• Must demonstrate high integrity

• Experience in development of both small molecules and biologics, including ADCs, RCs, and/or IO (Immune Checkpoint Inhibitors)
• Experience in the development of platform studies
• Experience developing data and justification leading to successful Ph3 investment decisions
• Experience in the treatment of and/or development of agents for the treatment of prostate cancer
• Experience in due diligence (e.g. asset evaluation, assessment of new biomarker and diagnostic tools)

Essential

Desirable

• Graduate degree such as a PharmD, PhD, or an MD/PhD
• Industry experience in drug development including experience in early phase clinical drug development and regulatory knowledge
• Strong knowledge and understanding of the Oncology therapeutic area with experience in diverse biological modalities
• Understanding of the evolving clinical landscape in oncology
• Demonstrated experience leading and motivating teams in a highly matrixed environment
• Proven record of cultivating and managing internal and external cross-functional collaborations
• Demonstrated success in influencing colleagues and senior leaders in various departments
• Must demonstrate high integrity

• Experience in development of both small molecules and biologics, including ADCs, RCs, and/or IO (Immune Checkpoint Inhibitors)
• Experience in the development of platform studies
• Experience developing data and justification leading to successful Ph3 investment decisions
• Experience in the treatment of and/or development of agents for the treatment of prostate cancer
• Experience in due diligence (e.g. asset evaluation, assessment of new biomarker and diagnostic tools)

• Functional heads driving key components of early drug development such as: Clinical, Translational Medicine, Drug Supply, Regulatory, Discovery, Biometrics
• Early and Late GPLs and Franchise Heads across the organization to ensure strategic alignment, to maximize value of AZ assets, and to share and interpret critical data enabling Ph2 to Ph3 transitions
• Enterprise-Level Strategy Heads and key Tumor Council Members

• External investigators
• External partners co-developing combination regimens with AZ assets

The annual base pay ranges from 246,070 - 369,104. Hourly and salaried non-exempt employees will also be paid overtime pay when working qualifying overtime hours. Base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience.  In addition, our positions offer a short-term incentive bonus opportunity; eligibility to participate in our equity-based long-term incentive program (salaried roles), to receive a retirement contribution (hourly roles), and commission payment eligibility (sales roles). Benefits offered included a qualified retirement program [401(k) plan]; paid vacation and holidays; paid leaves; and, health benefits including medical, prescription drug, dental, and vision coverage in accordance with the terms and conditions of the applicable plans. Additional details of participation in these benefit plans will be provided if an employee receives an offer of employment. If hired, employee will be in an “at-will position” and the Company reserves the right to modify base pay (as well as any other discretionary payment or compensation program) at any time, including for reasons related to individual performance, Company or individual department/team performance, and market factors. 

Date Posted

Closing Date

Our mission is to build an inclusive environment where equal employment opportunities are available to all applicants and employees. In furtherance of that mission, we welcome and consider applications from all qualified candidates, regardless of their protected characteristics. If you have a disability or special need that requires accommodation, please complete the corresponding section in the application form.